Systemic lupus erythematosus (SLE) is an autoimmune disease that affects the body's connective tissues. SLE, like all auto-immune conditions, occurs when the body produces abnormal antibodies that attack normal body tissue as if it were a foreign invader.
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects the body’s connective tissues. SLE occurs when the body produces abnormal antibodies that attack normal body tissue as if it were a foreign invader. Normally, the immune system protects the body by producing antibodies that destroy foreign invaders, such as bacteria or viruses. In people with lupus, the immune system produces antibodies that target the body’s own healthy cells, leading to tissue damage, organ failure, disability, or death.
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects the body’s connective tissues. SLE occurs when the body produces abnormal antibodies that attack normal body tissue as if it were a foreign invader. Normally, the immune system protects the body by producing antibodies that destroy foreign invaders, such as bacteria or viruses. In people with lupus, the immune system produces antibodies that target the body’s own healthy cells, leading to tissue damage, organ failure, disability, or death.
Lupus symptoms can vary widely. There are many symptoms associated with SLE because it can affect so many different parts of the body.
Many people diagnosed with lupus don’t have all the same symptoms.
Men and women with lupus may experience:
While the exact cause of lupus is not fully understood, a combination of defective genes and environmental factors are believed to trigger lupus. SLE imposes multiple complications on the affected person, their family, and their health care provider. To complicate matters, SLE is often misdiagnosed or overlooked by health care providers.
Did you know that there are different kinds of lupus? Here are the three main types:
This type is usually limited to the skin and may present with a positive anti-nuclear antibody (ANA) test. Symptoms include mucosal ulcerations, a “butterfly” rash, hair loss, thick scarring lesions, skin pigmentation changes, hives, and Raynaud’s phenomena.
Systemic lupus can involve any system of the body, including joints and major organs like the heart, lungs, kidneys, and brain. When lupus progresses and begins to involve multiple systems, it is diagnosed as SLE.
This type is generally caused by certain medications. Symptoms are similar to systemic lupus but usually disappear when the medications are discontinued. Anticonvulsant drugs, like Tegretol (carbamazepine), can induce lupus-like symptoms in some patients.
SLE is a difficult disease to understand and control with drug-based medicine. Conventional treatment typically involves corticosteroids and NSAIDs. Prednisone, a widely used corticosteroid, suppresses inflammation associated with SLE. NSAIDs are often prescribed to back up corticosteroids. Anti-malarial drugs like hydroxychloroquine are used to calm SLE manifestations. Toxic drugs like methotrexate, azathioprine, and cyclophosphamide are used to reduce steroid dosage.
Variable results are obtained from these approaches, and side effects must be weighed against SLE symptoms. Long-term use of prednisone can cause many side effects. NSAIDs can cause gastrointestinal damage. Toxic drugs often fail to achieve remission and cause significant side effects like hepatitis, nausea, vomiting, bone marrow depression, pancreatitis, skin rashes, and delayed healing.
Alternatives to conventional drug treatments are becoming popular due to the lack of a cure for SLE and the desire for treatments with fewer side effects. Autoimmune disease does not happen by chance. Investigate potential causes of your SLE, like dental problems or unresolved stress. A good start is detox followed by the Adrenal Fatigue Program.
This is one of my main treatments of choice. It makes sense to ensure your adrenal glands are working well since they produce cortisol, the body’s main anti-inflammatory hormone. Many patients with autoimmune diseases need:
1. Digestive work
2. Detoxification
3. Adrenal gland rejuvenation
DHEA is a hormone made by the adrenal glands. It boosts immune function, improves mood and energy, and influences longevity. DHEA has shown benefits for SLE, rheumatoid arthritis, multiple sclerosis, diabetes, and certain cancers. DHEA is currently unavailable in NZ but can be ordered online from the USA. Work with a knowledgeable health-care professional rather than self-prescribe.
Studies show DHEA can reduce prednisone dosage, lower flare-ups, and improve well-being in SLE patients. Some side effects like acne and mild hirsutism were reported. DHEA therapy should be monitored by a professional to balance benefits and side effects.
One alternative therapy gaining acceptance overseas is the use of DHEA, a hormone made by the adrenal glands. DHEA is a natural hormone that is made by your adrenal glands, and the most abundant hormone made by the adrenal glands is DHEA. After DHEA is made by these glands it goes into the bloodstream, and from then on it travels all over the body and goes into your cells, where it is converted into male hormones k
Essential fatty acids and dietary oils have positive effects on SLE. Flaxseed oil has shown to improve antibody profiles and kidney inflammation in lupus patients. About one to two tablespoons per day can lower cholesterol and extend the lifespan of those with chronic SLE. I recommend Waihi Bush flaxseed oil.
Vitamin D deficiency is common in SLE patients due to sunlight sensitivity. Supplementation of vitamins A and D may benefit SLE patients. Cod liver oil, a rich source of these vitamins, is recommended. Consult a health care practitioner before taking high doses.
Free radical damage plays a role in SLE development. Antioxidant supplements like vitamins A, E, beta carotene, and selenium may improve disease status. Antioxidants can enhance immune function and reduce inflammation.
Food allergies and sensitivities can impact autoimmune diseases like SLE. Identifying and eliminating food triggers can benefit SLE patients. Diet plays a significant role in SLE management. Alfalfa seeds, which contain L-canavanine, can exacerbate SLE symptoms. Cooking destroys these effects without reducing the lipid-lowering properties.
SLE is difficult to manage due to its unknown cause and the varied response to treatments. Conventional drugs can be beneficial but have significant side effects. Alternatives like DHEA, antioxidants, and omega-3 fatty acids show promise in reducing disease activity and side effects. Testing for food allergies is recommended. Explore all treatment options with your health care professional. With proper support and a positive outlook, SLE patients can lead normal and productive lives.
Wallace DJ. The Lupus Book: A Guide for Patients and Their Families. New York: Oxford University Press; 1995:6-12, 66.
Rahman P, Humphrey-Murto S, Gladman DD, Urowitz MB. Cytotoxic therapy in systemic lupus erythematosus. Experience from a single center. Medicine (Baltimore) 1997;76:432-437.
Wise CM, Vuyyuru S, Roberts WN. Methotrexate in nonrenal lupus and undifferentiated connective tissue disease, a review of 36 patients. J Rheumatol 1996; 23:1005-1010.
Van Vollenhoven RF. Dehydroepiandrosterone in systemic lupus erythematosus. Rheum Dis Clin North Am 2000;26:349-362.
Formiga F, Moga I, Nolla JM, et al. The association of dehydroepiandrosterone sulphate levels with bone mineral density in systemic lupus erythematosus. Clin Exp Rheumatol 1997;15:387-392.
Clark WF, Parbtani A, Huff M, et al. Omega-3 fatty acid dietary supplementation in systemic lupus erythematosus. Kidney Int 1989;36:653-660.
Clark WF, Parbtani A, Huff MW, et al. Flaxseed: a potential treatment for lupus nephritis. Kidney Int 1995;48:475-480.
Muller K, Kriegbaum NJ, Baslund B, et al. Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus. Clin Rheumatol 1995;14:397-400.
Panush RS. Food induced allergic arthritis: clinical and serologic studies. J Rheumatol 1990;17:291-294.